{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T23:04:09Z","timestamp":1781305449731,"version":"3.54.1"},"reference-count":117,"publisher":"BMJ","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gut"],"published-print":{"date-parts":[[2009,1]]},"abstract":"<jats:p>Cancer of the oesophagus, gastro-oesophageal junction (GOJ) and stomach remains a major health problem worldwide. The evidence base for the optimal management of patients with operable oesophago-gastric cancer is evolving. Accepted approaches include preoperative chemotherapy followed by surgery (oesophageal cancer), chemo-radiotherapy alone (oesophageal cancer) and perioperative chemotherapy (gastric and gastro-oesophageal adenocarcinomas). The underlying principles behind neoadjuvant therapy are to improve resectability of the tumour by tumour shrinkage\/downstaging and to treat occult metastatic disease as early as possible. The response rate to cytotoxic therapy is about 40% in oesophago-gastric cancer. Available evidence suggests that a favourable histopathological response to cytotoxic therapy may be a useful positive predictive marker in oesophago-gastric cancer. However, the ability to predict tumour response in routine clinical practice is difficult and is an area of intense investigation. There is evolving evidence for the role of predictive biomarkers in cancer in general and oesophago-gastric cancer in particular. We provide an overview on the current status of radiological and biological predictive biomarkers. We have focussed on clinical translational investigations and, where appropriate, provided pre-clinical insights. Whether predictive markers will be routinely incorporated in clinical practice remains to be seen as biomarker research is expensive and the data generated from these investigations are complex. It is clear that a concerted international effort between academia and industry is critical if personalised medicine as a practical reality for our cancer patients is to be realised.<\/jats:p>","DOI":"10.1136\/gut.2008.155861","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T14:08:27Z","timestamp":1229522907000},"page":"127-143","source":"Crossref","is-referenced-by-count":66,"title":["Biomarkers of response to therapy in oesophago-gastric cancer"],"prefix":"10.1136","volume":"58","author":[{"given":"K R","family":"Fareed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Kaye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I N","family":"Soomro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M","family":"Ilyas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S L","family":"Parsons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Madhusudan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2008,12,17]]},"reference":[{"key":"2025121221411673000_58.1.127.1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO;2-2"},{"key":"2025121221411673000_58.1.127.2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1991.03460100089030"},{"key":"2025121221411673000_58.1.127.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.semradonc.2006.09.003"},{"key":"2025121221411673000_58.1.127.4","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199321850-00002"},{"key":"2025121221411673000_58.1.127.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2004.01.001"},{"key":"2025121221411673000_58.1.127.6","first-page":"107","article-title":"A comparison of outcome after resection for squamous cell carcinomas and adenocarcinomas of the esophagus and cardia.","volume":"175","author":"Law","year":"1992","journal-title":"Surg Gynecol Obstet"},{"key":"2025121221411673000_58.1.127.7","doi-asserted-by":"publisher","DOI":"10.1097\/00000658-199211000-00010"},{"key":"2025121221411673000_58.1.127.8","doi-asserted-by":"crossref","first-page":"406S","DOI":"10.1378\/chest.103.4_Supplement.406S","article-title":"Multimodality therapy for esophageal carcinoma \u2013 an update.","volume":"103","author":"Orringer MB","year":"1993","journal-title":"Chest"},{"key":"2025121221411673000_58.1.127.9","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5223(95)70428-0"},{"key":"2025121221411673000_58.1.127.10","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055531"},{"key":"2025121221411673000_58.1.127.11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08651-8"},{"key":"2025121221411673000_58.1.127.12","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19940601)73:11<2680::AID-CNCR2820731105>3.0.CO;2-C"},{"key":"2025121221411673000_58.1.127.13","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11660"},{"key":"2025121221411673000_58.1.127.14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.06.7801"},{"key":"2025121221411673000_58.1.127.15","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1200\/JCO.2001.19.12.3058","article-title":"Prediction of response to preoperative chemotherapy in adenocarcinomas of the esophagogastric junction by metabolic imaging.","volume":"19","author":"Weber","year":"2001","journal-title":"J Clin Oncol"},{"key":"2025121221411673000_58.1.127.16","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(07)70244-9"},{"key":"2025121221411673000_58.1.127.17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2003.06.574"},{"key":"2025121221411673000_58.1.127.18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.04.001"},{"key":"2025121221411673000_58.1.127.19","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0934"},{"key":"2025121221411673000_58.1.127.20","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2005.09.004"},{"key":"2025121221411673000_58.1.127.21","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1200\/JCO.1988.6.10.1653","article-title":"Fluorouracil: biochemistry and pharmacology.","volume":"6","author":"Pinedo","year":"1988","journal-title":"J Clin Oncol"},{"key":"2025121221411673000_58.1.127.22","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074"},{"key":"2025121221411673000_58.1.127.23","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-2960"},{"issue":"(Suppl 2)","key":"2025121221411673000_58.1.127.24","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(01)00414-2","article-title":"Rational development of capecitabine.","volume":"38","author":"Venturini","year":"2002","journal-title":"Eur J Cancer"},{"key":"2025121221411673000_58.1.127.25","doi-asserted-by":"publisher","DOI":"10.1097\/00001813-200402000-00001"},{"key":"2025121221411673000_58.1.127.26","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6602891"},{"key":"2025121221411673000_58.1.127.27","doi-asserted-by":"publisher","DOI":"10.1007\/s10038-005-0339-4"},{"key":"2025121221411673000_58.1.127.28","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2005.08.008","article-title":"Polymorphism at the 3\u2032-UTR of the thymidylate synthase gene: a potential predictor for outcomes in Caucasian patients with esophageal adenocarcinoma treated with preoperative chemoradiation.","volume":"64","author":"Liao","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121221411673000_58.1.127.29","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22235"},{"key":"2025121221411673000_58.1.127.30","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1200\/JCO.1998.16.1.309","article-title":"ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy.","volume":"16","author":"Metzger","year":"1998","journal-title":"J Clin Oncol"},{"key":"2025121221411673000_58.1.127.31","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1200\/JCO.1996.14.1.176","article-title":"Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival.","volume":"14","author":"Lenz","year":"1996","journal-title":"J Clin Oncol"},{"key":"2025121221411673000_58.1.127.32","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.22080"},{"key":"2025121221411673000_58.1.127.33","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1605"},{"key":"2025121221411673000_58.1.127.34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2000.tb00866.x"},{"key":"2025121221411673000_58.1.127.35","first-page":"761","article-title":"Roles of thymidylate synthase and dihydropyrimidine dehydrogenase in tumor progression and sensitivity to 5-fluorouracil in human gastric cancer.","volume":"22","author":"Terashima","year":"2002","journal-title":"Anticancer Res"},{"key":"2025121221411673000_58.1.127.36","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2007.01.006"},{"key":"2025121221411673000_58.1.127.37","doi-asserted-by":"publisher","DOI":"10.1309\/1U6X4L9XFJLJV940"},{"key":"2025121221411673000_58.1.127.38","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-1387"},{"key":"2025121221411673000_58.1.127.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2004.10.035"},{"key":"2025121221411673000_58.1.127.40","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0042"},{"key":"2025121221411673000_58.1.127.41","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19980501)82:9<1626::AID-CNCR5>3.0.CO;2-8"},{"key":"2025121221411673000_58.1.127.42","doi-asserted-by":"publisher","DOI":"10.1080\/07357900600632082"},{"key":"2025121221411673000_58.1.127.43","first-page":"49","article-title":"Thymidylate synthase protein expression: Association with response to neoadjuvant chemotherapy and resection for locally advanced gastric and gastroesophageal adenocarcinoma.","volume":"1","author":"Alexander","year":"1995","journal-title":"Cancer J Sci Am"},{"key":"2025121221411673000_58.1.127.44","doi-asserted-by":"publisher","DOI":"10.1159\/000011968"},{"key":"2025121221411673000_58.1.127.45","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2004.02.019"},{"key":"2025121221411673000_58.1.127.46","first-page":"2149","article-title":"p53, bcl-2 and thymidine phosphorylase as predictive markers of chemotherapy in patients with advanced and recurrent gastric cancer.","volume":"21","author":"Kikuyama","year":"2001","journal-title":"Anticancer Res"},{"key":"2025121221411673000_58.1.127.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2006.09.006"},{"key":"2025121221411673000_58.1.127.48","doi-asserted-by":"publisher","DOI":"10.1006\/bbrc.1994.2306"},{"key":"2025121221411673000_58.1.127.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.07.001"},{"key":"2025121221411673000_58.1.127.50","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206933"},{"key":"2025121221411673000_58.1.127.51","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1007\/BF03256260","article-title":"Cancer pharmacogenomics: role of DNA repair genetic polymorphisms in individualizing cancer therapy.","volume":"11","author":"Gossage","year":"2007","journal-title":"Mol Diagn Ther"},{"key":"2025121221411673000_58.1.127.52","doi-asserted-by":"publisher","DOI":"10.1021\/cr040483f"},{"key":"2025121221411673000_58.1.127.53","doi-asserted-by":"publisher","DOI":"10.1016\/S0079-6603(04)79004-2"},{"key":"2025121221411673000_58.1.127.54","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.biochem.73.011303.073723"},{"key":"2025121221411673000_58.1.127.55","doi-asserted-by":"publisher","DOI":"10.1038\/cr.2008.8"},{"key":"2025121221411673000_58.1.127.56","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200767130-00007"},{"key":"2025121221411673000_58.1.127.57","doi-asserted-by":"publisher","DOI":"10.1007\/BF02698032"},{"issue":"(18S)","key":"2025121221411673000_58.1.127.58","doi-asserted-by":"crossref","first-page":"2512","DOI":"10.1200\/jco.2007.25.18_suppl.2512","article-title":"ERCC1 mRNA expression and XRCC1 polymorphism as predictive factors for overall survival in gastric cancer patients receiving platinum based chemotherapy.","volume":"25","author":"Wei","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025121221411673000_58.1.127.59","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.04.8322"},{"key":"2025121221411673000_58.1.127.60","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.6640"},{"key":"2025121221411673000_58.1.127.61","doi-asserted-by":"crossref","first-page":"6032","DOI":"10.3748\/wjg.v12.i37.6032","article-title":"Xeroderma pigmentosum group D 751 polymorphism as a predictive factor in resected gastric cancer treated with chemo-radiotherapy.","volume":"12","author":"Zarate","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2025121221411673000_58.1.127.62","doi-asserted-by":"crossref","unstructured":"Wei J Zou Z Qian X .ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen. Br J Cancer 2008;98:1398\u2013402.","DOI":"10.1038\/sj.bjc.6604317"},{"key":"2025121221411673000_58.1.127.63","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604211"},{"key":"2025121221411673000_58.1.127.64","first-page":"2371","article-title":"High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil.","volume":"4","author":"Metzger","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025121221411673000_58.1.127.65","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-03-0079"},{"key":"2025121221411673000_58.1.127.66","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1179\/joc.2006.18.5.514","article-title":"Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival.","volume":"18","author":"Leichman","year":"2006","journal-title":"J Chemother"},{"key":"2025121221411673000_58.1.127.67","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1038\/sj.bjc.6601976","article-title":"Quantitative c-erbB-2 but not c-erbB-1 mRNA expression is a promising marker to predict minor histopathologic response to neoadjuvant radiochemotherapy in oesophageal cancer.","volume":"91","author":"Miyazono","year":"2004","journal-title":"Br J Cancer"},{"key":"2025121221411673000_58.1.127.68","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdl430"},{"key":"2025121221411673000_58.1.127.69","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2007.09.006"},{"key":"2025121221411673000_58.1.127.70","doi-asserted-by":"publisher","DOI":"10.1245\/ASO.2002.04.030"},{"key":"2025121221411673000_58.1.127.71","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2297"},{"key":"2025121221411673000_58.1.127.72","doi-asserted-by":"publisher","DOI":"10.1038\/nrc776"},{"key":"2025121221411673000_58.1.127.73","doi-asserted-by":"publisher","DOI":"10.1021\/bi001603q"},{"key":"2025121221411673000_58.1.127.74","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2004.tb03169.x"},{"key":"2025121221411673000_58.1.127.75","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0215(20010320)95:2<92::AID-IJC1016>3.0.CO;2-9"},{"key":"2025121221411673000_58.1.127.76","first-page":"1241","article-title":"Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.","volume":"13","author":"Warnecke-Eberz","year":"2005","journal-title":"Oncol Rep"},{"key":"2025121221411673000_58.1.127.77","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-3063"},{"key":"2025121221411673000_58.1.127.78","first-page":"198","article-title":"Cyclooxygenase-2 expression in human esophageal carcinoma.","volume":"59","author":"Zimmermann","year":"1999","journal-title":"Cancer Res"},{"key":"2025121221411673000_58.1.127.79","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.3748\/wjg.v13.i25.3466","article-title":"COX-2 expression in gastric cancer and its relationship with angiogenesis using tissue microarray.","volume":"13","author":"Mao","year":"2007","journal-title":"World J Gastroenterol"},{"key":"2025121221411673000_58.1.127.80","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-2373"},{"key":"2025121221411673000_58.1.127.81","first-page":"1469","article-title":"Biological markers as a predictor for response and prognosis of unresectable gastric cancer patients treated with 5-fluorouracil and cis-platinum.","volume":"4","author":"Boku","year":"1998","journal-title":"Clin Cancer Res"},{"key":"2025121221411673000_58.1.127.82","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hyi194"},{"key":"2025121221411673000_58.1.127.83","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0142(19981101)83:9<1917::AID-CNCR6>3.0.CO;2-1"},{"key":"2025121221411673000_58.1.127.84","doi-asserted-by":"publisher","DOI":"10.1007\/s005950050190"},{"key":"2025121221411673000_58.1.127.85","doi-asserted-by":"publisher","DOI":"10.1136\/mp.56.5.286"},{"key":"2025121221411673000_58.1.127.86","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/sj.bjc.6602322","article-title":"The predictive value of p53, p53R2, and p21 for the effect of chemoradiation therapy on oesophageal squamous cell carcinoma.","volume":"92","author":"Okumura","year":"2005","journal-title":"Br J Cancer"},{"key":"2025121221411673000_58.1.127.87","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604037"},{"key":"2025121221411673000_58.1.127.88","doi-asserted-by":"publisher","DOI":"10.1016\/S0360-3016(03)00782-X"},{"key":"2025121221411673000_58.1.127.89","first-page":"6461","article-title":"Epidermal growth factor receptor, p53 mutation, and pathological response predict survival in patients with locally advanced esophageal cancer treated with preoperative chemoradiotherapy.","volume":"9","author":"Gibson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025121221411673000_58.1.127.90","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.8810"},{"key":"2025121221411673000_58.1.127.91","doi-asserted-by":"publisher","DOI":"10.1038\/74651"},{"key":"2025121221411673000_58.1.127.92","doi-asserted-by":"publisher","DOI":"10.1038\/35025220"},{"key":"2025121221411673000_58.1.127.93","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206816"},{"key":"2025121221411673000_58.1.127.94","doi-asserted-by":"publisher","DOI":"10.1038\/nrc704"},{"key":"2025121221411673000_58.1.127.95","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.20215"},{"key":"2025121221411673000_58.1.127.96","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hym057"},{"key":"2025121221411673000_58.1.127.97","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6600129"},{"key":"2025121221411673000_58.1.127.98","doi-asserted-by":"publisher","DOI":"10.1016\/S1010-7940(02)00044-1"},{"key":"2025121221411673000_58.1.127.99","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtcvs.2003.12.034"},{"key":"2025121221411673000_58.1.127.100","doi-asserted-by":"publisher","DOI":"10.1023\/A:1012827221844"},{"key":"2025121221411673000_58.1.127.101","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1609"},{"key":"2025121221411673000_58.1.127.102","doi-asserted-by":"publisher","DOI":"10.1093\/jjco\/hym089"},{"key":"2025121221411673000_58.1.127.103","doi-asserted-by":"publisher","DOI":"10.1038\/73439"},{"key":"2025121221411673000_58.1.127.104","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2007.06.009"},{"key":"2025121221411673000_58.1.127.105","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2007.00435.x"},{"key":"2025121221411673000_58.1.127.106","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1038\/nature06915","article-title":"Enabling personalized cancer medicine through analysis of gene-expression patterns.","volume":"452","author":"van \u2018t Veer","year":"2008","journal-title":"Nature"},{"key":"2025121221411673000_58.1.127.107","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1038\/nature06916","article-title":"Mining the plasma proteome for cancer biomarkers.","volume":"452","author":"Hanash","year":"2008","journal-title":"Nature"},{"key":"2025121221411673000_58.1.127.108","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature06914","article-title":"Translating insights from the cancer genome into clinical practice.","volume":"452","author":"Chin","year":"2008","journal-title":"Nature"},{"key":"2025121221411673000_58.1.127.109","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-06-1577"},{"key":"2025121221411673000_58.1.127.110","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.03.3688"},{"key":"2025121221411673000_58.1.127.111","first-page":"1345","article-title":"Expression profiling of esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy: clinical implications.","volume":"28","author":"Ashida","year":"2006","journal-title":"Int J Oncol"},{"key":"2025121221411673000_58.1.127.112","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9550-1"},{"key":"2025121221411673000_58.1.127.113","doi-asserted-by":"publisher","DOI":"10.1038\/nature06917"},{"key":"2025121221411673000_58.1.127.114","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1368"},{"key":"2025121221411673000_58.1.127.115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijrobp.2007.06.039","article-title":"Fluorine-18-labeled fluoromisonidazole positron emission and computed tomography-guided intensity-modulated radiotherapy for head and neck cancer: a feasibility study.","volume":"70","author":"Lee","year":"2008","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025121221411673000_58.1.127.116","first-page":"2307","article-title":"Chromosomal instability rather than p53 mutation is associated with response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma.","volume":"9","author":"Ott","year":"2003","journal-title":"Clin Cancer Res"},{"key":"2025121221411673000_58.1.127.117","first-page":"4505","article-title":"HIF-1alpha mRNA is not associated with histopathological regression following neoadjuvant chemoradiation in esophageal cancer.","volume":"26","author":"Ling","year":"2006","journal-title":"Anticancer Res"}],"container-title":["Gut"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/gut.2008.155861","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:41:25Z","timestamp":1765604485000},"score":1,"resource":{"primary":{"URL":"https:\/\/gut.bmj.com\/lookup\/doi\/10.1136\/gut.2008.155861"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,12,17]]},"references-count":117,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2008,12,17]]},"published-print":{"date-parts":[[2009,1]]}},"alternative-id":["10.1136\/gut.2008.155861"],"URL":"https:\/\/doi.org\/10.1136\/gut.2008.155861","relation":{},"ISSN":["0017-5749","1468-3288"],"issn-type":[{"value":"0017-5749","type":"print"},{"value":"1468-3288","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,12,17]]}}}